5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serious O
Cardiovascular O
Events O
: O
Sudden O
death O
has O
been O
reported O
in O
association O
with O
CNS O
stimulant O
treatment O
at O
usual O
doses O
in O
children O
and O
adolescents O
with O
structural O
cardiac O
abnormalities O
or O
other O
serious O
heart O
problems O
. O

Sudden O
death O
, O
stroke O
, O
and O
myocardial O
infarction O
have O
been O
reported O
in O
adults O
taking O
stimulant O
drugs O
at O
usual O
doses O
for O
ADHD O
. O

Stimulant O
products O
generally O
should O
not O
be O
used O
in O
patients O
with O
known O
structural O
cardiac O
abnormalities O
, O
cardiomyopathy O
, O
serious O
heart O
rhythm O
abnormalities O
, O
coronary O
artery O
disease O
, O
or O
other O
serious O
heart O
problems O
. O

( O
5.1 O
) O
* O
Increase O
in O
Blood O
Pressure O
: O
Monitor O
patients O
for O
changes O
in O
heart O
rate O
and O
blood O
pressure O
and O
use O
with O
caution O
in O
patients O
for O
whom O
an O
increase O
in O
blood O
pressure O
or O
heart O
rate O
would O
be O
problematic O
. O

( O
5.1 O
) O
* O
Psychiatric O
Adverse O
Events O
: O
Use O
of O
stimulants O
may O
cause O
treatment-emergent O
psychotic O
or O
manic O
symptoms O
in O
patients O
with O
no O
prior O
history O
, O
or O
exacerbation O
of O
symptoms O
in O
patients O
with O
pre-existing O
psychiatric O
illness O
. O

Clinical O
evaluation O
for O
Bipolar O
Disorder O
is O
recommended O
prior O
to O
stimulant O
use O
. O

Monitor O
for O
aggressive O
behavior O
. O

( O
5.2 O
) O
* O
Seizures O
: O
Stimulants O
may O
lower O
the O
convulsive O
threshold O
. O

Discontinue O
in O
the O
presence O
of O
seizures O
. O

( O
5.3 O
) O
* O
Priapism O
: O
Cases O
of O
painful O
and O
prolonged O
penile O
erections O
and O
priapism O
have O
been O
reported O
with O
methylphenidate O
products O
. O

Immediate O
medical O
attention O
should O
be O
sought O
if O
signs O
or O
symptoms O
of O
prolonged O
penile O
erections O
or O
priapism O
are O
observed O
( O
5.4 O
) O
* O
Peripheral O
Vasculopathy O
, O
including O
Raynaud O
's O
phenomenon O
: O
Stimulants O
used O
to O
treat O
ADHD O
are O
associated O
with O
peripheral O
vasculopathy O
, O
including O
Raynaud O
's O
phenomenon O
. O

Careful O
observation O
for O
digital O
changes O
is O
necessary O
during O
treatment O
with O
ADHD O
stimulants O
. O

( O
5.5 O
) O
* O
Long-Term O
Suppression O
of O
Growth O
: O
Monitor O
height O
and O
weight O
at O
appropriate O
intervals O
in O
pediatric O
patients O
. O

( O
5.6 O
) O
* O
Chemical O
Leukoderma O
: O
Daytrana O
use O
may O
result O
in O
a O
persistent O
loss O
of O
skin O
pigmentation O
at O
and O
around O
the O
application O
site O
. O

Loss O
of O
pigmentation O
, O
in O
some O
cases O
, O
has O
been O
reported O
at O
other O
sites O
distant O
from O
the O
application O
site O
. O

Monitor O
for O
signs O
of O
skin O
depigmentation O
. O

Discontinue O
Daytrana O
if O
it O
occurs O
. O

( O
5.7 O
) O
* O
Contact O
Sensitization O
: O
Use O
of O
Daytrana O
may O
lead O
to O
contact O
sensitization O
. O

Treatment O
should O
be O
discontinued O
if O
contact O
sensitization O
is O
suspected O
. O

Erythema O
is O
commonly O
seen O
with O
use O
of O
Daytrana O
and O
is O
not O
by O
itself O
an O
indication O
of O
sensitization O
. O

However O
, O
contact O
sensitization O
should O
be O
suspected O
if O
erythema O
is O
accompanied O
by O
evidence O
of O
a O
more O
intense O
local O
reaction O
( O
edema O
, O
papules O
, O
vesicles O
) O
that O
does O
not O
significantly O
improve O
within O
48 O
hours O
or O
spreads O
beyond O
the O
patch O
site O
. O

( O
5.8 O
) O
* O
Visual O
Disturbance O
: O
Difficulties O
with O
accommodation O
and O
blurring O
of O
vision O
have O
been O
reported O
with O
stimulant O
treatment O
. O

( O
5.9 O
) O
* O
External O
Heat O
: O
Patients O
should O
be O
advised O
to O
avoid O
exposing O
the O
Daytrana O
application O
site O
to O
direct O
external O
heat O
sources O
. O

When O
heat O
is O
applied O
to O
Daytrana O
after O
patch O
application O
, O
both O
the O
rate O
and O
extent O
of O
absorption O
are O
significantly O
increased O
. O

( O
5.10 O
) O
* O
Hematologic O
monitoring O
: O
Periodic O
CBC O
, O
differential O
, O
and O
platelet O
counts O
are O
advised O
during O
prolonged O
therapy O
. O

( O
5.11 O
) O
5.1 O
Serious O
Cardiovascular O
Events O
Sudden O
Death O
and O
Pre-existing O
Structural O
Cardiac O
Abnormalities O
or O
Other O
Serious O
Heart O
Problems O
Children O
and O
Adolescents O
Sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
has O
been O
reported O
in O
association O
with O
CNS O
stimulant O
treatment O
at O
usual O
doses O
in O
children O
and O
adolescents O
with O
structural B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
or O
other O
serious O
heart B-Not_AE_Candidate
problems I-Not_AE_Candidate
. O

Although O
some O
serious O
heart B-Not_AE_Candidate
problems I-Not_AE_Candidate
alone O
carry O
an O
increased O
risk O
of O
sudden B-NonOSE_AE
death I-NonOSE_AE
, O
stimulant O
products O
generally O
should O
not O
be O
used O
in O
children O
or O
adolescents O
with O
known O
serious O
structural B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
cardiomyopathy B-Not_AE_Candidate
, O
serious O
heart B-Not_AE_Candidate
rhythm I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
or O
other O
serious O
cardiac B-Not_AE_Candidate
problems I-Not_AE_Candidate
that O
may O
place O
them O
at O
increased O
vulnerability O
to O
the O
sympathomimetic O
effects O
of O
a O
stimulant O
drug O
. O

Adults O
Sudden B-OSE_Labeled_AE
deaths I-OSE_Labeled_AE
, O
stroke B-OSE_Labeled_AE
, O
and O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
have O
been O
reported O
in O
adults O
taking O
stimulant O
drugs O
at O
usual O
doses O
for O
ADHD B-Not_AE_Candidate
. O

Although O
the O
role O
of O
stimulants O
in O
these O
adult O
cases O
is O
also O
unknown O
, O
adults O
have O
a O
greater O
likelihood O
than O
children O
of O
having O
serious O
structural B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
cardiomyopathy B-Not_AE_Candidate
, O
serious O
heart B-Not_AE_Candidate
rhythm I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
coronary B-Not_AE_Candidate
artery I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
or O
other O
serious O
cardiac B-Not_AE_Candidate
problems I-Not_AE_Candidate
. O

Adults O
with O
such O
abnormalities O
should O
also O
generally O
not O
be O
treated O
with O
stimulant O
drugs O
. O

Hypertension O
and O
Other O
Cardiovascular O
Conditions O
Stimulant O
medications O
cause O
a O
modest O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
average O
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
about O
2-4 O
mmHg O
) O
and O
average O
heart O
rate O
( O
about O
3-6 O
bpm O
) O
, O
and O
individuals O
may O
have O
larger O
increases O
. O

While O
the O
mean O
changes O
alone O
would O
not O
be O
expected O
to O
have O
short-term O
consequences O
, O
all O
patients O
should O
be O
monitored O
for O
larger O
changes B-NonOSE_AE
in I-NonOSE_AE
heart I-NonOSE_AE
rate I-NonOSE_AE
and O
blood O
pressure O
. O

Caution O
is O
indicated O
in O
treating O
patients O
whose O
underlying O
medical O
conditions O
might O
be O
compromised O
by O
increases B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
or O
heart O
rate O
, O
e.g. O
, O
those O
with O
pre-existing O
hypertension B-Not_AE_Candidate
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
recent O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
or O
ventricular B-Not_AE_Candidate
arrhythmia I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Assessing O
Cardiovascular O
Status O
in O
Patients O
Being O
Treated O
With O
Stimulant O
Medications O
Children O
, O
adolescents O
, O
or O
adults O
who O
are O
being O
considered O
for O
treatment O
with O
stimulant O
medications O
should O
have O
a O
careful O
history O
( O
including O
assessment O
for O
a O
family O
history O
of O
sudden B-Not_AE_Candidate
death I-Not_AE_Candidate
or O
ventricular B-Not_AE_Candidate
arrhythmia I-Not_AE_Candidate
) O
and O
physical O
exam O
to O
assess O
for O
the O
presence O
of O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
and O
should O
receive O
further O
cardiac O
evaluation O
if O
findings O
suggest O
such O
disease O
( O
e.g. O
, O
electrocardiogram O
and O
echocardiogram O
) O
. O

Patients O
who O
develop O
symptoms O
such O
as O
exertional B-NonOSE_AE
chest I-NonOSE_AE
pain I-NonOSE_AE
, O
unexplained O
syncope B-NonOSE_AE
, O
or O
other O
symptoms O
suggestive O
of O
cardiac B-NonOSE_AE
disease I-NonOSE_AE
during O
stimulant O
treatment O
should O
undergo O
a O
prompt O
cardiac O
evaluation O
. O

5.2 O
Psychiatric O
Adverse O
Events O
Pre-Existing O
Psychosis O
Administration O
of O
stimulants O
may O
exacerbate B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
of I-OSE_Labeled_AE
behavior O
disturbance O
and O
thought I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
in O
patients O
with O
a O
pre-existing O
psychotic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Bipolar O
Illness O
Particular O
care O
should O
be O
taken O
in O
using O
stimulants O
to O
treat O
ADHD B-Not_AE_Candidate
in O
patients O
with O
comorbid O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
because O
of O
concern O
for O
possible O
induction B-OSE_Labeled_AE
of I-OSE_Labeled_AE
a I-OSE_Labeled_AE
mixed/ O
manic I-OSE_Labeled_AE
episode I-OSE_Labeled_AE
in O
such O
patients O
. O

Prior O
to O
initiating O
treatment O
with O
a O
stimulant O
, O
patients O
with O
comorbid O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
should O
be O
adequately O
screened O
to O
determine O
if O
they O
are O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
; O
such O
screening O
should O
include O
a O
detailed O
psychiatric B-NonOSE_AE
history O
, O
including O
a O
family O
history O
of O
suicide B-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
. O

Emergence O
of O
New O
Psychotic O
or O
Manic O
Symptoms O
Treatment O
emergent O
psychotic B-OSE_Labeled_AE
or O
manic O
symptoms I-OSE_Labeled_AE
, O
e.g. O
, O
hallucinations B-OSE_Labeled_AE
, O
delusional B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
, O
or O
mania B-OSE_Labeled_AE
in O
children O
and O
adolescents O
without O
a O
prior O
history O
of O
psychotic B-NonOSE_AE
illness I-NonOSE_AE
or O
mania B-NonOSE_AE
can O
be O
caused O
by O
stimulants O
at O
usual O
doses O
. O

If O
such O
symptoms O
occur O
, O
consideration O
should O
be O
given O
to O
a O
possible O
causal O
role O
of O
the O
stimulant O
, O
and O
discontinuation O
of O
treatment O
may O
be O
appropriate O
. O

In O
a O
pooled O
analysis O
of O
multiple O
short O
term O
, O
placebo-controlled O
studies O
, O
such O
symptoms O
occurred O
in O
about O
0.1 O
% O
( O
4 O
patients O
with O
events O
out O
of O
3,482 O
exposed O
to O
methylphenidate O
or O
amphetamine O
for O
several O
weeks O
at O
usual O
doses O
) O
of O
stimulant-treated O
patients O
compared O
to O
none O
in O
placebo-treated O
patients O
. O

Aggression O
Aggressive B-NonOSE_AE
behavior I-NonOSE_AE
or O
hostility B-NonOSE_AE
is O
often O
observed O
in O
children O
and O
adolescents O
with O
ADHD B-Not_AE_Candidate
, O
and O
has O
been O
reported O
in O
clinical O
trials O
and O
the O
postmarketing O
experience O
of O
some O
medications O
indicated O
for O
the O
treatment O
of O
ADHD B-Not_AE_Candidate
. O

Although O
there O
is O
no O
systematic O
evidence O
that O
stimulants O
cause O
aggressive B-NonOSE_AE
behavior I-NonOSE_AE
or O
hostility B-NonOSE_AE
, O
patients O
beginning O
treatment O
for O
ADHD B-Not_AE_Candidate
should O
be O
monitored O
for O
the O
appearance O
of O
or O
worsening B-NonOSE_AE
of I-NonOSE_AE
aggressive I-NonOSE_AE
behavior I-NonOSE_AE
or O
hostility B-NonOSE_AE
. O

5.3 O
Seizures B-OSE_Labeled_AE
There O
is O
some O
clinical O
evidence O
that O
stimulants O
may O
lower B-OSE_Labeled_AE
the I-OSE_Labeled_AE
convulsive I-OSE_Labeled_AE
threshold I-OSE_Labeled_AE
in O
patients O
with O
prior O
history O
of O
seizures B-Not_AE_Candidate
, O
in O
patients O
with O
prior O
EEG B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
in O
absence O
of O
seizures B-NonOSE_AE
, O
and O
, O
very O
rarely O
, O
in O
patients O
without O
a O
history O
of O
seizures B-NonOSE_AE
and O
no O
prior O
EEG O
evidence O
of O
seizures B-NonOSE_AE
. O

In O
the O
presence O
of O
seizures B-NonOSE_AE
, O
the O
drug O
should O
be O
discontinued O
. O

5.4 O
Priapism O
Prolonged B-OSE_Labeled_AE
and O
painful O
erections I-OSE_Labeled_AE
, O
sometimes O
requiring O
surgical O
intervention O
, O
have O
been O
reported O
with O
methylphenidate O
products O
in O
both O
pediatric O
and O
adult O
patients O
. O

Priapism B-OSE_Labeled_AE
was O
not O
reported O
with O
drug O
initiation O
but O
developed O
after O
some O
time O
on O
the O
drug O
, O
often O
subsequent O
to O
an O
increase O
in O
dose O
. O

Priapism B-NonOSE_AE
has O
also O
appeared O
during O
a O
period O
of O
drug O
withdrawal O
( O
drug O
holidays O
or O
during O
discontinuation O
) O
. O

Patients O
who O
develop O
abnormally B-NonOSE_AE
sustained I-NonOSE_AE
or O
frequent O
and O
painful O
erections I-NonOSE_AE
should O
seek O
immediate O
medical O
attention O
. O

5.5 O
Peripheral O
Vasculopathy O
, O
including O
Raynaud O
's O
phenomenon O
Stimulants O
, O
including O
Daytrana O
, O
used O
to O
treat O
ADHD B-Not_AE_Candidate
are O
associated O
with O
peripheral B-OSE_Labeled_AE
vasculopathy I-OSE_Labeled_AE
, O
including O
Raynaud B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
phenomenon I-OSE_Labeled_AE
. O

Signs O
and O
symptoms O
are O
usually O
intermittent O
and O
mild O
; O
however O
, O
very O
rare O
sequelae O
include O
digital B-NonOSE_AE
ulceration I-NonOSE_AE
and/or O
soft B-NonOSE_AE
tissue I-NonOSE_AE
breakdown I-NonOSE_AE
. O

Effects O
of O
peripheral B-OSE_Labeled_AE
vasculopathy I-OSE_Labeled_AE
, O
including O
Raynaud B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
phenomenon I-OSE_Labeled_AE
, O
were O
observed O
in O
post-marketing O
reports O
at O
different O
times O
and O
at O
therapeutic O
doses O
in O
all O
age O
groups O
throughout O
the O
course O
of O
treatment O
. O

Signs O
and O
symptoms O
generally O
improve O
after O
reduction O
in O
dose O
or O
discontinuation O
of O
drug O
. O

Careful O
observation O
for O
digital B-NonOSE_AE
changes I-NonOSE_AE
is O
necessary O
during O
treatment O
with O
ADHD B-Not_AE_Candidate
stimulants O
. O

Further O
clinical O
evaluation O
( O
e.g. O
, O
rheumatology O
referral O
) O
may O
be O
appropriate O
for O
certain O
patients O
5.6 O
Long-Term O
Suppression O
of O
Growth O
Careful O
follow-up O
of O
weight O
and O
height O
in O
children O
ages O
7 O
to O
10 O
years O
who O
were O
randomized O
to O
either O
methylphenidate O
or O
non-medication O
treatment O
groups O
over O
14 O
months O
, O
as O
well O
as O
in O
naturalistic O
subgroups O
of O
newly O
methylphenidate-treated O
and O
non-medication O
treated O
children O
over O
36 O
months O
( O
to O
the O
ages O
of O
10 O
to O
13 O
years O
) O
, O
suggests O
that O
consistently O
medicated O
children O
( O
i.e. O
, O
treatment O
for O
7 O
days O
per O
week O
throughout O
the O
year O
) O
have O
a O
temporary O
slowing B-OSE_Labeled_AE
in I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( O
on O
average O
, O
a O
total O
of O
about O
2 O
cm O
less B-OSE_Labeled_AE
growth I-OSE_Labeled_AE
in I-OSE_Labeled_AE
height I-OSE_Labeled_AE
and O
2.7 O
kg O
less B-OSE_Labeled_AE
growth I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
over O
3 O
years O
) O
, O
without O
evidence O
of O
growth O
rebound O
during O
this O
period O
of O
development O
. O

Published O
data O
are O
inadequate O
to O
determine O
whether O
chronic O
use O
of O
amphetamines O
may O
cause O
a O
similar O
suppression B-NonOSE_AE
of I-NonOSE_AE
growth I-NonOSE_AE
, O
however O
, O
it O
is O
anticipated O
that O
they O
likely O
have O
this O
effect O
as O
well O
. O

Therefore O
, O
growth O
should O
be O
monitored O
during O
treatment O
with O
stimulants O
, O
and O
patients O
who O
are O
not B-NonOSE_AE
growing I-NonOSE_AE
or O
gaining O
height O
or O
weight O
as O
expected O
may O
need O
to O
have O
their O
treatment O
interrupted O
. O

5.7 O
Chemical B-OSE_Labeled_AE
Leukoderma I-OSE_Labeled_AE
Daytrana O
use O
may O
result O
in O
a O
persistent O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
pigmentation I-OSE_Labeled_AE
at I-OSE_Labeled_AE
and I-OSE_Labeled_AE
around I-OSE_Labeled_AE
the I-OSE_Labeled_AE
application I-OSE_Labeled_AE
site I-OSE_Labeled_AE
. O

Loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
pigmentation I-OSE_Labeled_AE
, O
in O
some O
cases O
, O
has O
been O
reported O
at O
other O
sites O
distant O
from O
the O
application O
site O
. O

Chemical B-NonOSE_AE
leukoderma I-NonOSE_AE
can O
mimic O
the O
appearance O
of O
vitiligo B-NonOSE_AE
, O
particularly O
when O
the O
loss B-NonOSE_AE
of I-NonOSE_AE
skin I-NonOSE_AE
pigmentation I-NonOSE_AE
involves I-NonOSE_AE
areas I-NonOSE_AE
distant I-NonOSE_AE
from I-NonOSE_AE
the I-NonOSE_AE
application I-NonOSE_AE
site I-NonOSE_AE
. O

Individuals O
with O
a O
history O
of O
vitiligo B-Not_AE_Candidate
and/or O
a O
family O
history O
of O
vitiligo B-Not_AE_Candidate
may O
be O
more O
at O
risk O
. O

Skin B-NonOSE_AE
depigmentation I-NonOSE_AE
may O
persist O
even O
after O
Daytrana O
use O
is O
discontinued O
. O

Monitor O
for O
signs O
of O
skin B-NonOSE_AE
depigmentation I-NonOSE_AE
, O
and O
advise O
patients O
to O
immediately O
inform O
their O
healthcare O
provider O
if O
changes B-NonOSE_AE
in I-NonOSE_AE
skin I-NonOSE_AE
pigmentation I-NonOSE_AE
occur O
. O

Discontinue O
the O
Daytrana O
patch O
in O
patients O
with O
chemical B-NonOSE_AE
leukoderma I-NonOSE_AE
. O

5.8 O
Contact O
Sensitization O
In O
an O
open-label O
study O
of O
305 O
subjects O
conducted O
to O
characterize O
dermal B-NonOSE_AE
reactions I-NonOSE_AE
in O
children O
with O
ADHD B-Not_AE_Candidate
treated O
with O
Daytrana O
using O
a O
9-hour O
wear O
time O
, O
one O
subject O
( O
0.3 O
% O
) O
was O
confirmed O
by O
patch O
testing O
to O
be O
sensitized B-OSE_Labeled_AE
to I-OSE_Labeled_AE
methylphenidate I-OSE_Labeled_AE
( O
allergic B-OSE_Labeled_AE
contact I-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
) O
. O

This O
subject O
experienced O
erythema B-OSE_Labeled_AE
and O
edema O
at I-OSE_Labeled_AE
Daytrana I-OSE_Labeled_AE
application I-OSE_L
abeled B-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
sites I-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
- I-OSE_Labeled_AE
OSE I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
Labeled I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
with I-OSE_Labeled_AE
concurrent O
urticarial B-OSE_Labeled_AE
lesions I-OSE_Labeled_AE
on I-OSE_Labeled_AE
the I-OSE_Labeled_AE
abdomen I-OSE_Labeled_AE
and O
legs O
resulting O
in O
treatment O
discontinuation O
. O

This O
subject O
was O
not O
transitioned O
to O
oral O
methylphenidate O
. O

Use O
of O
Daytrana O
may O
lead O
to O
contact B-OSE_Labeled_AE
sensitization I-OSE_Labeled_AE
. O

Daytrana O
should O
be O
discontinued O
if O
contact B-NonOSE_AE
sensitization I-NonOSE_AE
is O
suspected O
. O

Erythema B-OSE_Labeled_AE
is O
commonly O
seen O
with O
use O
of O
Daytrana O
and O
is O
not O
by O
itself O
an O
indication O
of O
sensitization B-NonOSE_AE
. O

However O
, O
contact B-NonOSE_AE
sensitization I-NonOSE_AE
should O
be O
suspected O
if O
erythema B-NonOSE_AE
is O
accompanied O
by O
evidence O
of O
a O
more O
intense O
local B-NonOSE_AE
reaction I-NonOSE_AE
( O
edema O
, O
papules O
, O
vesicles O
) O
that O
does O
not O
significantly O
improve O
within O
48 O
hours O
or O
spreads O
beyond O
the O
patch O
site O
. O

Confirmation O
of O
a O
diagnosis O
of O
contact B-NonOSE_AE
sensitization I-NonOSE_AE
( O
allergic B-NonOSE_AE
contact I-NonOSE_AE
dermatitis I-NonOSE_AE
) O
may O
require O
further O
diagnostic O
testing O
. O

Patients O
sensitized B-OSE_Labeled_AE
from I-OSE_Labeled_AE
use I-OSE_Labeled_AE
of I-OSE_Labeled_AE
Daytrana I-OSE_Labeled_AE
, O
as O
evidenced O
by O
development O
of O
an O
allergic B-OSE_Labeled_AE
contact I-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
may O
develop O
systemic B-OSE_Labeled_AE
sensitization I-OSE_Labeled_AE
or O
other O
systemic O
reactions O
if O
methylphenidate-containing O
products O
are O
taken O
via O
other O
routes O
, O
e.g. O
, O
orally O
. O

Manifestations O
of O
systemic B-NonOSE_AE
sensitization I-NonOSE_AE
may O
include O
a O
flare B-NonOSE_AE
- I-NonOSE_AE
up I-NonOSE_AE
of I-NonOSE_AE
previous I-NonOSE_AE
dermatitis I-NonOSE_AE
or O
of O
prior O
positive O
patch-test O
sites O
, O
or O
generalized B-NonOSE_AE
skin I-NonOSE_AE
eruptions I-NonOSE_AE
in O
previously O
unaffected O
skin O
. O

Other O
systemic O
reactions O
may O
include O
headache B-NonOSE_AE
, O
fever B-NonOSE_AE
, O
malaise B-NonOSE_AE
, O
arthralgia B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
or O
vomiting B-NonOSE_AE
. O

No O
cases O
of O
systemic B-NonOSE_AE
sensitization I-NonOSE_AE
have O
been O
observed O
in O
clinical O
trials O
of O
Daytrana O
. O

Patients O
who O
develop O
contact B-NonOSE_AE
sensitization I-NonOSE_AE
to O
Daytrana O
and O
require O
oral O
treatment O
with O
methylphenidate O
should O
be O
initiated O
on O
oral O
medication O
under O
close O
medical O
supervision O
. O

It O
is O
possible O
that O
some O
patients O
sensitized B-NonOSE_AE
to I-NonOSE_AE
methylphenidate I-NonOSE_AE
by O
exposure O
to O
Daytrana O
may O
not O
be O
able O
to O
take O
methylphenidate O
in O
any O
form O
. O

5.9 O
Visual B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
Difficulties B-OSE_Labeled_AE
with I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
and O
blurring B-OSE_Labeled_AE
of I-OSE_Labeled_AE
vision I-OSE_Labeled_AE
have O
been O
reported O
with O
stimulant O
treatment O
. O

5.10 O
Patients O
Using O
External O
Heat O
Patients O
should O
be O
advised O
to O
avoid O
exposing O
the O
Daytrana O
application O
site O
to O
direct B-NonOSE_AE
external I-NonOSE_AE
heat I-NonOSE_AE
sources I-NonOSE_AE
, O
such O
as O
hair O
dryers O
, O
heating O
pads O
, O
electric O
blankets O
, O
heated O
water O
beds O
, O
etc. O
, O
while O
wearing O
the O
patch O
. O

When O
heat O
is O
applied O
to O
Daytrana O
after O
patch O
application O
, O
both O
the O
rate O
and O
extent O
of O
absorption O
are O
significantly O
increased O
. O

The O
temperature-dependent O
increase O
in O
methylphenidate O
absorption O
can O
be O
greater O
than O
2-fold O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

This O
increased O
absorption O
can O
be O
clinically O
significant O
and O
can O
result O
in O
overdose O
of O
methylphenidate O
[ O
see O
Overdosage O
( O
10 O
) O
] O
. O

5.11 O
Hematologic O
Monitoring O
Periodic O
CBC O
, O
differential O
, O
and O
platelet O
counts O
are O
advised O
during O
prolonged O
therapy O
. O

